source
- Beam Therapeutics reports successful pivotal trial of base editing sickle cell therapyBeam Therapeutics announced that its base editing treatment, ristoglogene autogetemcel (risto‑cel), met its primary goal in a pivotal trial for sickle cell disease. The trial showed the therapy cou…
- STAT+: GLP-1s are given an FDA warning for rare eye condition riskThe FDA warned that GLP-1 drugs carry a potential risk of a rare but serious eye condition sometimes referred to as an “eye stroke.”STAT · 4h ago↗ source